Research Papers:

Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Hong-Kai Wang, Fang-Nin Wan, Wei-Jie Gu, Yao Zhu, Bo Dai, Guo-Hai Shi, Hai-Liang Zhang _ and Ding-Wei Ye

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:68943-68953. https://doi.org/10.18632/oncotarget.12126

Metrics: PDF 1396 views  |   HTML 1892 views  |   ?  


Hong-Kai Wang1,2,#, Fang-Nin Wan1,2,#, Wei-Jie Gu1,2, Yao Zhu1,2, Bo Dai1,2, Guo-Hai Shi1,2, Hai-Liang Zhang1,2, Ding-Wei Ye1,2

1Department of Urology, Shanghai Cancer Center, Fudan University, Shanghai, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

#First authors

Correspondence to:

Hai-Liang Zhang, email: [email protected]

Ding-Wei Ye, email: [email protected]

Keywords: eosinophil percentage, metastatic renal cell carcinoma, tyrosine kinase inhibitor, prognosis, prognostic models

Received: January 10, 2016     Accepted: September 12, 2016     Published: September 20, 2016


Background: We tried to investigate the prognostic significance of post-treatment eosinophil percentage(Eo %) in metastatic renal cell carcinoma(mRCC) patients undertaking sorafenib.

Results: The median OS for the entire sorafenib treatment period was 21.9 months (95% CI: 17.2–25.9 months). Of the 282 mRCC patients, 101 patients experienced an elevated post-treatment Eo % within two months. Median OS of post-treatment Eo % elevated group and non-elevated group were 42.9 months and 16.8 months(p=0.000). After adding post-treatment Eo % into a modified MSKCC model or Heng’s model, 43 and 41 patients were reclassified into favorable group, 5 and 9 patients were reclassified to intermediate group respectively.

Methods: mRCC patients treated with sorafenib from 2006 to 2015 in were evaluated. Pre- and post-treatment Eo % were assessed. Oncologic outcomes were analyzed by overall survival and tumor response rate. Predictive parameters were assessed in a Cox proportional hazard model.

Conclusions: Our study demonstrates that an early elevation of Eo % after sorafenib treatment is a strong predictor of good prognosis. Eo % can be a good supplementary for prognostic models using pre-treatment parameters.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12126